- Home
- SEER vs ANVS Comparison
SEER vs ANVS Comparison
Compare SEER & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | ANVS |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 111.3M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SEER | ANVS |
|---|---|---|
| Price | $1.68 | $2.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 254.6K | ★ 385.1K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.40 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,578,000.00 | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $25.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.62 | $1.11 |
| 52 Week High | $2.41 | $5.50 |
Technical Indicators
Market Signals| Indicator | SEER | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 41.81 |
| Support Level | N/A | $1.97 |
| Resistance Level | $1.97 | $2.29 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 18.42 | 23.39 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.